Navigation Links
Abaxis Reports Record Sales for the Third Quarter of Fiscal 2008
Date:1/31/2008

$0.13 $0.41 $0.33

Shares used in the calculation of net

income per share:

Weighted average common shares

outstanding - basic 21,561 20,766 21,441 20,547

Weighted average common shares

outstanding - diluted 22,359 21,939 22,208 21,871

ABAXIS, INC.

Condensed Balance Sheets

(Unaudited and in thousands)

December 31, March 31,

2007 2007

Current assets:

Cash and cash equivalents $11,792 $10,183

Short-term investments 43,966 35,028

Trade receivables, net 20,862 16,929

Inventories, net 18,020 14,813

Prepaid expenses 677 1,321

Net deferred tax asset - current 4,133 8,979

Total current assets 99,450 87,253

Property and equipment, net 13,982 12,662

Intangible assets, net 394 450

Other assets 19 38

Net deferred tax asset - non-current 2,469 2,312

Total assets $116,314 $102,715

Current liabilities:

Accounts payable $7,047 $6,505

Accrued payroll and related expenses 3,587 3,830

Other accrued liabilities 1,422 1,169

Deferred revenue 780 917

Warranty reserve 1,157 315

Total current liabili
'/>"/>

SOURCE Abaxis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related medicine news :

1. Abaxis to Present at the CL King Best Ideas Conference 2007
2. Abaxis Launches The VetScan(R) HM5 a State-of-the-Art 5-Part Differential Veterinary Hematology Analyzer
3. Abaxis to Present at the 2007 UBS Global Life Science Conference
4. Abaxis Announces New Waived Kidney Check Panel Exclusively for Imaging and Radiology Centers
5. Abaxis to Report Second Quarter Fiscal 2008 Financial Results Wednesday, October 24, 2007
6. Abaxis Announces Appointment of New Distribution Partner in Japan
7. Abaxis Announces First Ever CLIA-Waived Comprehensive Metabolic Panel
8. Abaxis, Inc. to Present at the Fifth Annual Sidoti & Company Emerging Growth Conference
9. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
10. Haemacure Reports Third Quarter 2007 Results
11. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2008)... Open enrollment is now ha... cover expenses not covered by Medicare, and may a...ny consumers are now shopping online for instant q... Fort Collins, CO (PRWEB) November 21, 2008 -- Med...nt for Medicare Supplement plans . Medicare Adva...
(Date:11/21/2008)...inding may lead to new therapies for preterm labor... Researchers say they,ve found the switch that act...childbirth, a finding that may lead to therapies f...normally binds the protein IP on the surface of th...inactive during pregnancy. , But researchers f...
(Date:11/21/2008)..., TALLAHASSEE, Fla. -- A Florida State University... Wang has discovered an important new layer of reg...ad to a greater understanding of the way cancer be...al sciences at the College of Medicine, said the f...se cancer and could lead to the design of new drug...
(Date:11/21/2008)...OVELAND, Colo., Nov. 21 ...ed it will present at the New York Society of,Sec...Pharma Conference on,December 2, 2008 at 1177 Ave...he presentation is scheduled to begin at 9:35 a.m....be available via live webcast and for two weeks,f...
Breaking Medicine News(10 mins):Health News:MediGap Advisors Announces Open Enrollment for Medicare Supplement Plans 2
... a half months after his sexual organ was complete... to lead a normal life again after a Delhi hospita...The unmarried man from Uttar Pradesh underwent a s...he Sir Ganga Rama Hospital (SGRH), a leading priva...
...pproach to drug delivery has been achieved. This i...rong and stable glass made from organic material....he journal Science has reported the advanced proce...nsin-Madison and the National Institute of Standar...
...sh scientist was a consultant for a chemical compa...ossibility of developing cancer in the industry.//...demiologist, who died last year was known for havi... blamed in 1800 for having received $1,500 as dail...
...ian parliamentarians will attend a two-day confere...ple's elected representatives in combating the dis..., a worldwide network of individual parliamentaria...al assembly of Punjab (Pakistan), Pakistan Nationa...
Other Medicine News:Health News:Delhi Hospital Reattaches Amputated Penis 2Health News:Drugs Delivery Revolutionized by Extremely Stable Glass 2
(Date:11/20/2008)...w Jersey American Water has lifted the precaution...following municipalities in Middlesex, Somerset an... , , Dunellen , Edison , ...nfield , , , , Somerset County , ..., Green Brook , Hillsborough , ...
(Date:11/20/2008)...SE III TRIAL SHOW SIGNIFICANT, DECREASES IN P..., IN, FIBROMYALGIA PAT...ium, Nov. 20 /PRNewswire-FirstCall/,-- Jazz Pharm...xt Brussels: UCB),announced today positive prelim...e III pivotal clinical trials of sodium oxybate (J...
(Date:11/20/2008)...lk. It does a body good. And,now it,s doing it ev...,research, scientists at OncoNutrition(TM) have di...ate the body,s own production of antioxidants. , ...to:, http://www.prnewswire.com/mnr/eqwestgroup/361...apies, the chief scientist, Dr. David,Tsai, disco...
(Date:11/20/2008)...ll/ -- Duska Therapeutics,Inc., (OTC Bulletin Bo...its,pivotal Phase 3 ATPace clinical trial protoco...(SPA) procedure with the U.S. Food and Drug Admini...greement with the FDA, Duska intends to initiate a...olled and randomized Phase 3,clinical trial with ...
Breaking Medicine Technology:New Jersey American Water Lifts Precautionary Boil Water Advisory For Middlesex, Somerset and Union Counties 2Jazz Pharmaceuticals and UCB Announce Positive Phase III Results for Sodium Oxybate (JZP-6) in Fibromyalgia 2Jazz Pharmaceuticals and UCB Announce Positive Phase III Results for Sodium Oxybate (JZP-6) in Fibromyalgia 3Jazz Pharmaceuticals and UCB Announce Positive Phase III Results for Sodium Oxybate (JZP-6) in Fibromyalgia 4Jazz Pharmaceuticals and UCB Announce Positive Phase III Results for Sodium Oxybate (JZP-6) in Fibromyalgia 5Jazz Pharmaceuticals and UCB Announce Positive Phase III Results for Sodium Oxybate (JZP-6) in Fibromyalgia 6Photos: Peptides Discovered to Alleviate Chemotherapy Side Effects 2Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 2Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 3Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 4Nventa Provides Corporate Update and Advancement Plans for HspE7 Hsp 6 11 and Poly ICR 8168 1Nventa Provides Corporate Update and Advancement Plans for HspE7 Hsp 6 11 and Poly ICR 8168 2Nventa Provides Corporate Update and Advancement Plans for HspE7 Hsp 6 11 and Poly ICR 8168 3Nventa Provides Corporate Update and Advancement Plans for HspE7 Hsp 6 11 and Poly ICR 8168 4Nventa Provides Corporate Update and Advancement Plans for HspE7 Hsp 6 11 and Poly ICR 8168 5Nventa Provides Corporate Update and Advancement Plans for HspE7 Hsp 6 11 and Poly ICR 8168 6Nventa Provides Corporate Update and Advancement Plans for HspE7 Hsp 6 11 and Poly ICR 8168 7Nventa Provides Corporate Update and Advancement Plans for HspE7 Hsp 6 11 and Poly ICR 8168 8SEIU DVD Exposes How McCain Care Leaves Seniors Behind 27197 1SEIU DVD Exposes How McCain Care Leaves Seniors Behind 27197 2PreMD Inc Completes Secured Debenture Financing 27193 1PreMD Inc Completes Secured Debenture Financing 27193 2Thousands of Public Health Experts to Address Leading Issues at APHA Annual Meeting Oct 25 29 27190 1Thousands of Public Health Experts to Address Leading Issues at APHA Annual Meeting Oct 25 29 27190 2
....--(BUSINESS WIRE)--Apr 19, 2007 - Othera Pharmace...a, Professor of,Pharmacology and Executive Vice Pr...h Institute at Albany College of Pharmacy,will pr...antithrombotic effect of Othera,s lead compound, O...ms from previous ocular,studies on OT-551 eye drop...
...OAKS, Calif.--(BUSINESS WIRE)--Apr 19, 2007 - Amge...e "145 study", a,randomized, double-blind, placebo...R) (darbepoetin alfa) in 600 previously untreated,...er (SCLC),receiving platinum-containing chemothera...icant difference in risk of death (overall,surviva...
Other Medicine Technology:Othera Pharmaceuticals Announces Upcoming Presentation Based Upon,Expanded Understanding of Lead Compound Mechanism of Action 2Othera Pharmaceuticals Announces Upcoming Presentation Based Upon,Expanded Understanding of Lead Compound Mechanism of Action 3Othera Pharmaceuticals Announces Upcoming Presentation Based Upon,Expanded Understanding of Lead Compound Mechanism of Action 4Aranesp ``145 Study'' Shows No Difference in Survival in Patients,with Small-Cell Lung Cancer 2Aranesp ``145 Study'' Shows No Difference in Survival in Patients,with Small-Cell Lung Cancer 3Aranesp ``145 Study'' Shows No Difference in Survival in Patients,with Small-Cell Lung Cancer 4Aranesp ``145 Study'' Shows No Difference in Survival in Patients,with Small-Cell Lung Cancer 5Aranesp ``145 Study'' Shows No Difference in Survival in Patients,with Small-Cell Lung Cancer 6Aranesp ``145 Study'' Shows No Difference in Survival in Patients,with Small-Cell Lung Cancer 7
Olsen bayonet forceps, designed by Mr. Olsen in a configuration with 3 holes to make them lighter, more flexible, and also to ensure maximum grip for different procedures where there is limited acces
Cushing bayonet.
Angulated, blunt and pointed tips.
Straight, blunt tips.
Medicine Products: